PATENT CLAIM ANALYSIS

Application Number: 16016186
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "279000"]

Abstract:
The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

Claim (Index 13):
The solution of  claim 2 , comprising about 20 wt % of buprenorphine free base; wherein the weight ratio of N-methyl-2-pyrrolidone to polyethylene glycol is about 60:40.

Metadata:
- Claim Count in Document: 57.0
- Percentile: 94.0
- Lexical Diversity: 1.48485
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15857507', '14610818', '15623191', '13836134', '15334000']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.777354631271286
- 35 USC 102 Novelty (BERT): 0.5184567763067922
- Combined Prediction Score: 0.7514648457748367
- Mean Citation Score: 324.06961
- Max Citation Score: 333.98196
- Similarity Product: 289.9435307686472

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test